Media headlines about Chemed (NYSE:CHE) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chemed earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.5983879973527 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Chemed (NYSE:CHE) traded up $3.51 during trading on Tuesday, reaching $260.05. The company’s stock had a trading volume of 140,104 shares, compared to its average volume of 102,583. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $4,100.00, a P/E ratio of 57.92, a price-to-earnings-growth ratio of 2.87 and a beta of 1.16. Chemed has a one year low of $161.18 and a one year high of $261.91.
Chemed (NYSE:CHE) last released its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. Chemed’s revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.73 earnings per share. research analysts anticipate that Chemed will post 4.73 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on CHE shares. Royal Bank of Canada lifted their price objective on Chemed to $232.00 and gave the stock a “sector perform” rating in a report on Tuesday, October 31st. KeyCorp reaffirmed a “hold” rating on shares of Chemed in a report on Friday, October 27th. TheStreet raised Chemed from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Zacks Investment Research raised Chemed from a “hold” rating to a “buy” rating and set a $251.00 price objective for the company in a report on Thursday, November 2nd. Finally, ValuEngine cut Chemed from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $236.00.
In other Chemed news, VP Michael D. Witzeman sold 1,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $250.00, for a total transaction of $250,000.00. Following the completion of the transaction, the vice president now owns 3,334 shares of the company’s stock, valued at $833,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin J. Mcnamara sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total value of $2,234,200.00. Following the transaction, the chief executive officer now directly owns 170,016 shares of the company’s stock, valued at approximately $37,984,974.72. The disclosure for this sale can be found here. Insiders have sold 45,679 shares of company stock valued at $10,628,959 in the last three months. 4.90% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Chemed (CHE) Earns Media Impact Score of 0.18” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/09/chemed-che-earns-media-impact-score-of-0-18.html.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.